The new tax-inversion rules will trip up a lot of companies but they're not going to stop the practice, says former asst US attorney Mitchell Epner.» Read More
Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. It will compete with Nektar Therapeutics and AstraZeneca Plc's oral drug Movantik, approved by the FDA earlier this month for the same patient population.
Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. Salix, which is merging with Cosmo Pharmaceuticals SpA's Irish subsidiary, is in talks with Allergan Inc and Actavis Plc about a potential sale, sources have told Reuters in recent weeks.
Sept 26- T. Rowe Price, the second largest shareholder in Allergan Inc, said on Friday that it wants the company to hold off on making major moves before a Dec. 18 special shareholder meeting, and criticized the board's corporate governance.
Allergan Inc has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals Inc.. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.
Sept 24- Allergan Inc is in buyout talks with Actavis Plc in addition to Salix Pharmaceuticals Ltd, CNBC reported on Wednesday, as the company tries to fend off a takeover attempt by Valeant Pharmaceuticals Inc. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.
Sept 23- Moody's Investors Service said it may review the credit implications for pending tax-inversion deals in the healthcare and pharmaceutical sector if U.S. Affected companies include Medtronic Inc, Mylan Inc, Salix Pharmaceuticals, Auxilium Pharmaceuticals and AbbVie Inc..
NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Carmax Inc., down $5.01 to $47.80. Medtronic Inc., down $1.90 to $64.08.
NEW YORK, Sept 23- U.S. stocks were set for a lower open on Tuesday, putting the S&P on pace for a third straight fall, as conflict in the Middle East intensified and after the U.S.
NEW YORK, Sept 23- U.S.-listed shares of Tekmira Pharmaceuticals were climbing on Tuesday, up 8.9 percent at $25.70 as one of the most actively trades Nasdaq stocks as its Ebola drug will be one of several to be tested in West Africa in a bid to win fast-track trials.
NEW YORK, Sept 23- U.S. stock index futures were moving lower on Tuesday, putting the S&P on track for a third straight decline, as conflict in the Middle East intensified and after the U.S.
Some of Wednesday's midday movers:
NEW YORK, Sept 16- Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA, and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.
NEW YORK, Sept 16- Biotech stocks were trading higher on Tuesday, putting the Nasdaq biotechnology index on track to snap a three-day losing skid heading into the latter stages of trading.
Aug 19- Botox maker Allergan Inc has approached Salix Pharmaceuticals Ltd and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc, the Wall Street Journal said. Allergan and Salix declined to comment on the matter.
Some of Friday's midday movers:
The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.
Some of Monday's midday movers:
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
Some of Wednesday's midday movers:
*Alcoa tops expectations; shares up in premarket. *Citigroup may pay $7 billion to resolve probe: source. *Alcoa Inc rose 2 percent to $15.14 in premarket trading a day after reporting second-quarter adjusted earnings and revenue that topped expectations.